Bildkälla: Stockfoto

Cantargia: Closing in on a Licensing Deal? - Redeye

Redeye updates its view on Cantargia following a period that has brought promising trial results and the initiation of several new clinical projects. We adjust our estimates and valuation based on new timelines and an updated WACC.

Redeye updates its view on Cantargia following a period that has brought promising trial results and the initiation of several new clinical projects. We adjust our estimates and valuation based on new timelines and an updated WACC.
Börsvärldens nyhetsbrev
ANNONSER